Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
ANGPTL3 inhibition offers an LDL receptor-independent means to lower atherogenic particles spanning from TRLs to LDL, complementing traditional lipid-lowering therapies. Evinacumab is practice-changing in HoFH, and RNA agents may soon broaden applicability to patients with mixed dyslipidemia and residual cardiovascular risk, pending cardiovascular outcomes trials.
Authors
- André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
- Nicholas Marston (ORCID: https://orcid.org/0000-0001-6164-4617)
Institutions
- Brigham and Women's Hospital (US)
- Universidade Federal do Rio Grande do Sul (BR)
- Hospital Moinhos de Vento (BR)
- Thrombolysis in Myocardial Infarction Study Group (US)
Publication Details
- Journal
- Current Opinion in Lipidology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1097/mol.0000000000001013
- Citations
- 1
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39